The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients.

Nabeel KhanDhruvan PatelTyler PernesManthankumar PatelChinmay TrivediElina MedvedevaDawei XieYu-Xiao Yang

Published in: Crohn's & colitis 360 (2021)

Among IBD patients in remission, double switch was equally effective as compared to a single switch. This will help reassure the gastroenterologists who have concerns regarding the safety and efficacy of switching between multiple biosimilars for treating IBD.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
ulcerative colitis
prognostic factors
rheumatoid arthritis
patient reported outcomes
cross sectional
systemic lupus erythematosus
disease activity